No effect of Gilead’s remdesivir on corona patients: WHO
A World Health Organisation (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help Covid-19 patients is reliable, a scientist who evaluated it said on Friday, as the US company criticised its methodology. Trials were conducted on 11,266 adult patients in more than 30 countries.
In the trial, it was found remdesivir has failed to prevent Covid-19 deaths. Doses of remdesivir were given to Covid patients individually or in combination. The drug was originally developed to treat Ebola and Hepatitis C. Remdesivir is widely used in India to treat Covid patients.